Overview

Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations

Status:
Terminated
Trial end date:
2017-12-06
Target enrollment:
Participant gender:
Summary
The purpose of this phase 2a, proof of concept, open-label clinical study is to evaluate the efficacy and safety of etrasimod (APD334) in inflammatory bowel disease patients with active skin extra-intestinal manifestations.
Phase:
Phase 2
Details
Lead Sponsor:
Arena Pharmaceuticals